Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing.
vendredi 12 avril 2019

Lemtrada (alemtuzumab)

- Article en anglais :

As a temporary measure while the review is ongoing, Lemtrada should only be started in adults with relapsing-remitting multiple sclerosis that is highly active despite treatment with at least two disease-modifying therapies (a type of multiple sclerosis medicine) or where other disease-modifying therapies cannot be used. Patients being treated with Lemtrada who are benefitting from it may continue treatment in consultation with their doctor.

www.ema.europa.eu

- Dossier : Lemtrada.


www.ouest-france.fr, 12/04/19.